Antibiotic development — economic, regulatory and societal challenges
Antibiotic resistance is undoubtedly one of the greatest challenges to global health, and the emergence of resistance has outpaced the development of new antibiotics. However, investments by the pharmaceutical industry and biotechnology companies for research into and development of new antibiotics are diminishing. The public health implications of a drying antibiotic pipeline are recognized by policymakers, regulators and many companies. In this Viewpoint article, seven experts discuss the challenges that are contributing to the decline in antibiotic drug discovery and development, and the national and international initiatives aimed at incentivizing research and the development of new antibiotics to improve the economic feasibility of antibiotic development.
Display your AMR technology / product:
Global AMR Technologies Database
- Preventive – Diagnostic – Antimicrobial technologies
- Academia – Research Institutes – Start ups – SMEs – Multinationals
- Early research <-> near market
- Global reach for funding / co-development / licensing